Assess the Prognosis of Advanced Fibrosis due to NASH with a Simple Blood Test

Clinical Benefits of The Enhanced Liver Fibrosis (ELF™) Test

The Enhanced Liver Fibrosis test is a non-invasive blood test that measures three direct markers of fibrosis. Direct assessment of fibrosis has proven valuable for identifying patients at risk of progressing to cirrhosis and/or liver-related events.

The most widely studied direct marker is the ELF Test which can assess active, dynamic fibrosis rather than the damage it has caused. This allows the ELF Test to be used as a prognostic marker to identify the patients most at risk of progression to cirrhosis and LREs in patients with advanced fibrosis due to NASH.

ELF U.S. Test Kit
Consistent with U.S. Instructions for Use claims for the ELF Test, following identification of NASH patients with advanced fibrosis (≥F3) by FIB-4 >2.67, testing with ELF can determine the risk of progression to cirrhosis. An ELF score of <9.8 is associated with lower risk of disease progression. Although not described in the AACE guideline, an ELF score ≥11.3 is associated with a higher risk of progression to cirrhosis and liver related events.

Why choose the ELF Test?

Applicability in Different Patients/Conditions

Adults

Diabetes

Obesity

✔️

✔️

✔️

Economic Health Value

(Cost effectiveness)

Add clinical value

Improve ease and frequency of prognostic evaluation

✔️

✔️

Access

Simple Blood Test

Large Installed Base

✔️

✔️

Clinical Benefits of ELF

Ilustración de una enfermera recolectando un análisis de sangre en un paciente

Blood-based tests can readily support high-volume testing, do not require patient access to specialized imaging equipment or highly trained operators, and generally have lower incidence rates of failure and unreliable results reported for imaging modalities.1,2

  • Access noninvasive testing with a simple blood test available to all patients, including those with type 2 diabetes mellitus and obesity.2,3
  • Improve patient care by stratifying advanced NASH patients most at risk of progressing to cirrhosis and liver-related events.4
  • Enhance patient management with a blood test that facilitates more frequent prognostic assessments
Literature Compendium

This compendium highlights the ELF Test as a prognostic tool in those with advanced fibrosis due to NASH.

1
2
3
4
5
6
7
8